Free Trial
NASDAQ:CALT

Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis

Calliditas Therapeutics AB (publ) logo
$40.00 0.00 (0.00%)
As of 07/3/2025

About Calliditas Therapeutics AB (publ) Stock (NASDAQ:CALT)

Key Stats

Today's Range
$40.00
$40.00
50-Day Range
$40.00
$40.00
52-Week Range
$15.25
$43.00
Volume
N/A
Average Volume
10,339 shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

CALT Stock News Headlines

Banks aren’t ready for this altcoin—are you?
Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly positioned to fill it…
See More Headlines

CALT Stock Analysis - Frequently Asked Questions

Calliditas Therapeutics AB (publ)'s stock was trading at $40.0001 at the start of the year. Since then, CALT shares have increased by 0.0% and is now trading at $40.0001.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.09. The firm had revenue of $52.36 million for the quarter, compared to analysts' expectations of $42.89 million. Calliditas Therapeutics AB (publ) had a negative trailing twelve-month return on equity of 212.04% and a negative net margin of 30.18%.
Read the conference call transcript
.

Calliditas Therapeutics AB (publ) (CALT) raised $179 million in an initial public offering on Friday, June 5th 2020. The company issued 9,200,000 shares at a price of $19.50 per share. Citigroup, Jefferies and Stifel served as the underwriters for the IPO and Carnegie was co-manager.

Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Calliditas Therapeutics AB (publ) investors own include Advanced Micro Devices (AMD), Celsius (CELH), NIO (NIO), NVIDIA (NVDA), Reata Pharmaceuticals (RETA), Target (TGT) and Athenex (ATNX).

Company Calendar

Last Earnings
8/13/2024
Today
7/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CALT
Fax
N/A
Employees
180
Year Founded
2004

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.96 million
Pretax Margin
-29.40%

Debt

Sales & Book Value

Annual Sales
$1.60 billion
Price / Cash Flow
N/A
Book Value
$1.06 per share
Price / Book
37.74

Miscellaneous

Free Float
29,135,000
Market Cap
$1.19 billion
Optionable
Optionable
Beta
1.77

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:CALT) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners